Aerie Pharmaceuticals is an ophthalmic pharmaceutical company, dedicated to the discovery, development and commercialization of therapies for patients with open-angle glaucoma and other eye diseases.
Here’s what you should know:
1. Mr. LaRocca will report to Aerie’s Chairman and CEO Vicente Anido, Jr., PhD.
2. He comes to Aerie after serving as executive vice president and general counsel at Eagle Pharmaceuticals.
3. He’ll receive up to 70,000 shares of company stock and 18,000 shares of restricted stock. The shares will vest in four years, with 25 percent vesting on the first anniversary of his hire.
Mr. LaRocca said, “I believe Aerie is uniquely positioned as it continues to grow into a major ophthalmic pharmaceutical company. The Company is at a very exciting stage in its life cycle, and I look forward to contributing to the Company’s future success.”
More articles on leadership:
Former Surgery Partners CEO resigns from board & more — 8 ASC company key notes
5 tips to improve ASC implant payments
Driscoll Children’s Hospital raises $980k for new pediatric ICU, outpatient surgery center
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.